Clinical Trial Search

Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05

Primary: Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS) — 16.7 percentage of…

Primary: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2) — 6.7; 50 percentage of participants

Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Change in Tumor Volume — 10 Percent volume

Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…

Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders

Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected

Primary: Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour) — 1.7; 2.8 0-10 units on a scale

Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min

Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score

Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients

Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…

Primary: Proportion of True Positives for the Overall Detection of the Abnormal Parathyroid Adenoma — 0.75 proportion of participants

Primary: Percentage of Participants Diagnosed With Acromegaly — 5.8; 2.4 percentage of participants

Primary: Total-group Response Rate at Month 3 — 18.2 Percentage of participants

Primary: Progression-free Survival (PFS) at One Year — 11 months

Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months

Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120

Primary: Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 by Previous Treatment and Overall — 14.6; 13.8; 15.1; 14.6 Percentage of…

Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL

Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants

Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants

Primary: Percentage of Subjects That Achieved PRL Normalization as Defined by a Serum Prolactin Level Less Than 25ng/mL at Any Time Point During the Study Treatment Period. — 6…

Primary: Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration — 41.9; 40.8 percentage of participants

Primary: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period — 57.9 percentage of subjects…

Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001

Primary: Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 0; 8 participants

Primary: Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 — 31.3; 19.2; 39.4; 21.8 Percentage of Participants — p=0.007